NovaBay Pharmaceuticals, Inc.
5980 Horton Street
Suite 550
Emeryville,
CA 94608
United States - Map
Phone: 510-899-8800
Fax: 510-225-0371
Web Site: http://www.novabaypharma.com
| NovaBay Pharmaceuticals, Inc., a mid-stage biopharmaceutical company, focuses on developing product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments. Its proprietary Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are anti-infective molecules produced by white blood cells when defending the body against invading pathogens. These compounds could form a platform to create various products to address the needs in the treatment and prevention of bacterial and viral infections. The companys lead product candidate, NVC-422, is used for the treatment of eye, ear, and sinus infections, and for use in contact lens solutions, as well as to destroy bacteria in the bladder, and bacteria that have formed biofilm within the catheter. It also offers NVC-101, a proprietary solution of hypochlorous acid used as a wound cleanser and debriding agent. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions, as well as an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo, and other dermatological indications. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in August 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Ramin Najafi Ph.D., 50
Chairman, Chief Exec. Officer and Pres |
$
356.00K | N/A | Mr. Thomas J. Paulson , 62
Chief Financial Officer, Principal Accounting Officer and Treasurer |
$
250.00K | N/A | Mr. Robert R. Tufts Esq.,
Sec., Director, Member of Audit & Ethics Committee and Member of Nominating & Corp. Governance Committee |
$
14.00K | N/A | Dr. Behzad Khosrovi Ph.D., 65
VP of R&D |
$
238.00K | N/A | Dr. Mark Anderson Ph.D.,
Chief Scientific Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
